Literature DB >> 7694701

Decreased expression of CD23 on peripheral blood macrophages/monocytes during acute Kawasaki disease with coronary artery lesions.

S Furukawa1, T Matsubara, K Okumura, K Yabuta.   

Abstract

CD23 has been reported to be a macrophage/monocyte activation antigen. We focused on the expression of CD23 by peripheral blood macrophages/monocytes in 5 Kawasaki disease (KD) patients with coronary artery lesions (CAL) and compared these values with those of 35 patients without CAL. The expression of CD23 on peripheral blood macrophages/monocytes was assayed by a fluorescence-activated cell sorter using monoclonal antibodies CD23 and CD14. Absolute counts of CD23+CD14+ macrophages/monocytes in KD patients with CAL did not increase during the acute stage, while these values in KD patients without CAL increased. In addition, this decreased expression of CD23 on peripheral blood macrophages/monocytes in patients with CAL did not change during the acute stage, regardless of IVGG therapy. Our results suggest that the decreased expression of CD23 on peripheral blood macrophages/monocytes in patients with CAL is part of the regulatory system of CD23 antigen during acute KD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694701     DOI: 10.1159/000236580

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  3 in total

1.  Coronary artery involvement in Kawasaki disease--diagnosis and treatment.

Authors:  A Anand; A Anand
Journal:  West J Med       Date:  1995-10

2.  Soluble CD23 antigen in Kawasaki disease and other acute febrile illnesses.

Authors:  T Matsubara; S Furukawa; T Motohashi; K Okumura; K Yabuta
Journal:  Eur J Pediatr       Date:  1995-10       Impact factor: 3.183

Review 3.  Kawasaki Disease and Allergic Diseases.

Authors:  Po-Yu Huang; Ying-Hsien Huang; Mindy Ming-Huey Guo; Ling-Sai Chang; Ho-Chang Kuo
Journal:  Front Pediatr       Date:  2021-01-07       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.